Miao‐Zhen Qiu

8.1k total citations · 2 hit papers
165 papers, 4.9k citations indexed

About

Miao‐Zhen Qiu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Miao‐Zhen Qiu has authored 165 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 75 papers in Pulmonary and Respiratory Medicine and 40 papers in Surgery. Recurrent topics in Miao‐Zhen Qiu's work include Gastric Cancer Management and Outcomes (58 papers), Colorectal Cancer Treatments and Studies (37 papers) and Pancreatic and Hepatic Oncology Research (23 papers). Miao‐Zhen Qiu is often cited by papers focused on Gastric Cancer Management and Outcomes (58 papers), Colorectal Cancer Treatments and Studies (37 papers) and Pancreatic and Hepatic Oncology Research (23 papers). Miao‐Zhen Qiu collaborates with scholars based in China, United States and United Kingdom. Miao‐Zhen Qiu's co-authors include Rui‐Hua Xu, Hui Luo, De‐Shen Wang, Yuhong Li, Dong-sheng Zhang, Dajun Yang, Feng‐Hua Wang, Zhiqiang Wang, Yu-Hong Li and Feng-Hua Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Miao‐Zhen Qiu

160 papers receiving 4.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis

2022 226 citations Jin‐Fei Lin, Peishan Hu et al. Signal Transduction and Targeted Therapy profile →
Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response

2022 167 citations Zixian Wang, Yan‐Xing Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miao‐Zhen Qiu China	38	2.5k	1.6k	1.6k	1.3k	1.1k	165	4.9k
Yuxian Bai China	37	3.2k 1.3×	1.5k 0.9×	2.3k 1.5×	1.0k 0.8×	1.2k 1.1×	187	6.0k
Michele Orditura Italy	44	3.4k 1.3×	1.9k 1.2×	2.1k 1.3×	1.0k 0.8×	1.2k 1.1×	181	6.1k
Gennaro Galizia Italy	43	2.8k 1.1×	1.2k 0.7×	1.9k 1.2×	910 0.7×	1.3k 1.2×	140	5.2k
Allen Lee Cohn United States	38	4.7k 1.9×	1.5k 1.0×	2.4k 1.5×	1.3k 1.0×	875 0.8×	159	6.9k
Young Suk Park South Korea	41	4.0k 1.6×	1.3k 0.8×	2.3k 1.5×	1.1k 0.9×	1.9k 1.8×	227	6.3k
Vincenzo Catalano Italy	40	3.1k 1.2×	1.4k 0.9×	1.6k 1.0×	866 0.7×	1.2k 1.1×	124	5.1k
Filippo Pietrantonio Italy	37	2.9k 1.1×	1.1k 0.7×	1.5k 1.0×	1.2k 1.0×	1.1k 1.0×	298	5.0k
Alessandro Rizzo Italy	57	3.3k 1.3×	1.6k 1.0×	2.6k 1.7×	1.3k 1.0×	2.0k 1.9×	220	6.5k
Neeltje Steeghs Netherlands	37	2.8k 1.1×	1.7k 1.0×	1.9k 1.2×	857 0.7×	372 0.3×	242	5.4k
Toshifumi Wakai Japan	44	2.2k 0.9×	1.7k 1.1×	2.2k 1.4×	768 0.6×	2.6k 2.4×	346	6.0k

Countries citing papers authored by Miao‐Zhen Qiu

Since Specialization

Citations

This map shows the geographic impact of Miao‐Zhen Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miao‐Zhen Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miao‐Zhen Qiu more than expected).

Fields of papers citing papers by Miao‐Zhen Qiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miao‐Zhen Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miao‐Zhen Qiu. The network helps show where Miao‐Zhen Qiu may publish in the future.

Co-authorship network of co-authors of Miao‐Zhen Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Miao‐Zhen Qiu. A scholar is included among the top collaborators of Miao‐Zhen Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miao‐Zhen Qiu. Miao‐Zhen Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Fangfang, Xiaoli Wei, Weineng Feng, et al.. (2024). Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials. ESMO Open. 9(8). 103651–103651. 1 indexed citations

Qiu, Miao‐Zhen, Yuxian Bai, Jufeng Wang, et al.. (2024). Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. Signal Transduction and Targeted Therapy. 9(1). 349–349. 5 indexed citations

Li, Jibin, Wen‐Long Guan, Yuting Sun, et al.. (2024). The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis. Cancer Immunology Immunotherapy. 73(7). 132–132. 7 indexed citations

Qiu, Miao‐Zhen, Qingjian Chen, Qi Zhao, et al.. (2023). Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins. Cell Reports. 42(6). 112576–112576. 3 indexed citations

Xu, Rui‐Hua, Xiaoli Wei, Dongsheng Zhang, et al.. (2023). A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.. Journal of Clinical Oncology. 41(4_suppl). 352–352. 27 indexed citations

Han, Feng, Xiaoxiao Dong, Qingguang Lin, et al.. (2023). Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, open-label, randomised, controlled trial. European Radiology. 34(3). 1481–1492. 12 indexed citations

Luo, Fan, Han Li, Wenjuan Ma, et al.. (2023). The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cellular and Molecular Immunology. 21(1). 60–79. 37 indexed citations

Qiu, Miao‐Zhen, Yong Du, Liqiong Yang, et al.. (2022). High AKAP8L expression predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Cell International. 22(1). 90–90. 6 indexed citations

Wei, Xiaoli, Furong Liu, Jihong Liu, et al.. (2022). First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors. Nature Communications. 13(1). 7012–7012. 13 indexed citations

10.

Hu, Peishan, Ting Li, Jin‐Fei Lin, et al.. (2020). VDR–SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduction and Targeted Therapy. 5(1). 183–183. 46 indexed citations

11.

Wei, Xiaoli, Chao Ren, Feng‐Hua Wang, et al.. (2020). A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors. Cancer Communications. 40(8). 345–354. 33 indexed citations

12.

Nanda, Neha, Christian Gauthier, Matthäus Felsenstein, et al.. (2019). Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology. 156(6). 1905–1913. 45 indexed citations

13.

Bai, Long, Feng Wang, Chao Ren, et al.. (2016). Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine. 95(51). e4531–e4531. 13 indexed citations

14.

Wang, Zhiqiang, Dong-sheng Zhang, Nong Xu, et al.. (2016). Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chinese Journal of Cancer. 35(1). 8–8. 2 indexed citations

15.

Zhang, Lin, Gang Yuan, Yujing Fang, et al.. (2015). Increased WNT6 expression in tumor cells predicts unfavorable survival in esophageal squamous cell carcinoma patients.. PubMed Central. 8(9). 11421–7. 14 indexed citations

16.

Zhang, Lin, Miao‐Zhen Qiu, Ying Jin, et al.. (2015). Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.. PubMed. 8(9). 11084–91. 85 indexed citations

17.

Qiu, Miao‐Zhen, Yixin Zhou, Xinke Zhang, et al.. (2014). Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 14(1). 823–823. 55 indexed citations

18.

Qiu, Miao‐Zhen, Qian Li, Zhiqiang Wang, et al.. (2013). HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation. International Journal of Cancer. 134(10). 2468–2477. 52 indexed citations

19.

Chen, Dong-liang, De‐Shen Wang, Wen-jing Wu, et al.. (2012). Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 34(4). 803–811. 94 indexed citations

20.

Qiu, Miao‐Zhen, Zhao-Lei Zeng, Hui Luo, et al.. (2012). Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). Journal of Translational Medicine. 10(1). 21–21. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact